Icatibant

CAS : 130308-48-4

Ref. 3D-FI45882

Informations sur le produit

• Nom: Icatibant
• Synonymes: HOE 140D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Oic-Arg, Firazyr, Hoe140, L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-, (2S)-2-({[(3aS,7aS)-1-({2-[(2S)-2-{[(2S)-2-({[({(4R)-1-[(1-{2-({(2R)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1H-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid (non-preferred name)

Description

Icatibant is a 10 amino acid peptidomimetic of bradykinin and a selective antagonist to the bradykinin B2 receptor. Icabinant has been used for the treatment of attacks in patients with hereditary angioedema. Recent evidence has shown a link between dysregulated bradykinin‐mediated inflammation and acute respiratory distress syndrome (ARDS), a common complication in COVID-19 patients. Icatibant was proposed to inhibit excessive activation of the bradykinin B2 receptor during the SARS-CoV-2 infection, reducing the risk of ARDS._x000D_

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1,304.52 g/mol
• Formule: C₅₉H₈₉N₁₉O₁₃S
• Degré de pureté: Min. 95%